Research Study

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Principal Investigator 
Ging-Yuek Robin Hsiung

Overview

Body Locations and Systems 
Alzheimer's Disease
Disorders and Conditions 
Alzheimer's Disease
ClinicalTrials.gov# 
NCT02008357
Status 
Recruiting
Study Start/End 
Nov 17, 2014 to Dec 31, 2020
Locations 
UBC Hospital
Name/Title 
Benita Mudge, Research Coordinator
Phone 
604-822-7990
Email Address 
benita.mudge@vch.ca
Purpose of Study 

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.